Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study - PubMed (original) (raw)
Comparative Study
Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study
Peter P Zandi et al. Arch Gen Psychiatry. 2005 Feb.
Abstract
Background: Prior reports suggest reduced occurrence of dementia and Alzheimer disease (AD) in statin users, but, to our knowledge, no prospective studies relate statin use and dementia incidence.
Objective: To examine the association of statin use with both prevalence and incidence of dementia and AD.
Design: Cross-sectional studies of prevalence and incidence and a prospective study of incidence of dementia and AD among 5092 elderly residents (aged 65 years or older) of a single county. Participants were assessed at home in 1995-1997 and again in 1998-2000. A detailed visual inventory of medicines, including statins and other lipid-lowering agents, was collected at both assessments.
Main outcome measures: Diagnosis of dementia and of AD.
Results: From 4895 participants with data sufficient to determine cognitive status, we identified 355 cases of prevalent dementia (200 with AD) at initial assessment. Statin use was inversely associated with prevalence of dementia (adjusted odds ratio, 0.44; 95% confidence interval, 0.17-0.94). Three years later, we identified 185 cases of incident dementia (104 with AD) among 3308 survivors at risk. Statin use at baseline did not predict incidence of dementia or AD (adjusted hazard ratio for dementia, 1.19; 95% confidence interval, 0.53-2.34; adjusted hazard ratio for AD, 1.19; 95% confidence interval, 0.35-2.96), nor did statin use at follow-up (adjusted odds ratio for dementia, 1.04; 95% confidence interval, 0.56-1.81; adjusted odds ratio for AD, 0.85; 95% confidence interval, 0.32-1.88).
Conclusions: Although statin use might be less frequent in those with prevalent dementia, we found no association between statin use and subsequent onset of dementia or AD. Further research is warranted before costly dementia prevention trials with statins are undertaken.
Similar articles
- Statin use and the risk of incident dementia: the Cardiovascular Health Study.
Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, Hazzard WR, Zandi PP, Burke GL, Lyketsos CG, Bernick C, Kuller LH. Rea TD, et al. Arch Neurol. 2005 Jul;62(7):1047-51. doi: 10.1001/archneur.62.7.1047. Arch Neurol. 2005. PMID: 16009757 - Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis.
Zhou B, Teramukai S, Fukushima M. Zhou B, et al. Dement Geriatr Cogn Disord. 2007;23(3):194-201. doi: 10.1159/000099037. Epub 2007 Jan 25. Dement Geriatr Cogn Disord. 2007. PMID: 17259710 - Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adults.
Gray SL, Anderson ML, Crane PK, Breitner JC, McCormick W, Bowen JD, Teri L, Larson E. Gray SL, et al. J Am Geriatr Soc. 2008 Feb;56(2):291-5. doi: 10.1111/j.1532-5415.2007.01531.x. Epub 2007 Nov 27. J Am Geriatr Soc. 2008. PMID: 18047492 - [Prevalence and incidence of dementia among the very old. Review of the literature].
Ankri J, Poupard M. Ankri J, et al. Rev Epidemiol Sante Publique. 2003 Jun;51(3):349-60. Rev Epidemiol Sante Publique. 2003. PMID: 13130215 Review. French. - Do statins slow down Alzheimer's disease? A review.
Caballero J, Nahata M. Caballero J, et al. J Clin Pharm Ther. 2004 Jun;29(3):209-13. doi: 10.1111/j.1365-2710.2004.00560.x. J Clin Pharm Ther. 2004. PMID: 15153082 Review.
Cited by
- Is the LDL receptor involved in cortical amyloid protein clearance?
Abdulkarim Y, Hameed Z. Abdulkarim Y, et al. Neurochem Res. 2006 Jun;31(6):839-47. doi: 10.1007/s11064-006-9084-0. Epub 2006 Jul 14. Neurochem Res. 2006. PMID: 16841190 Review. - Is Alzheimer's Disease Risk Modifiable?
Serrano-Pozo A, Growdon JH. Serrano-Pozo A, et al. J Alzheimers Dis. 2019;67(3):795-819. doi: 10.3233/JAD181028. J Alzheimers Dis. 2019. PMID: 30776012 Free PMC article. Review. - Preventing Alzheimer's disease : separating fact from fiction.
Sano M, Grossman H, Van Dyk K. Sano M, et al. CNS Drugs. 2008;22(11):887-902. doi: 10.2165/00023210-200822110-00001. CNS Drugs. 2008. PMID: 18840031 Review. - Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions.
Walker D, Lue LF. Walker D, et al. Curr Neuropharmacol. 2007 Dec;5(4):232-43. doi: 10.2174/157015907782793667. Curr Neuropharmacol. 2007. PMID: 19305740 Free PMC article. - Medication Exposure and Risk of Dementia and Alzheimer's Disease.
Sharma N, An SSA, Kim SY. Sharma N, et al. Int J Mol Sci. 2024 Nov 29;25(23):12850. doi: 10.3390/ijms252312850. Int J Mol Sci. 2024. PMID: 39684561 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical